Earnings Scheduled For February 29, 2024 Companies Reporting Before The Bell • Frontline (
NYSE:FRO ) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.
VRCA Stock Earnings: Verrica Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024 VRCA stock results show that Verrica Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Why Is Dermatology-Focused Verrica Pharmaceuticals Stock Trading Lower On Wednesday? Verrica Pharmaceuticals shares positive preliminary results from Part 2 of its Phase 2 trial for VP-315 in treating basal cell carcinoma, showing promising tumor reduction and safety. No serious adverse events reported.
7 Short-Squeeze Stocks That Could Beat Down the Bears Panic can be a cruel emotion, especially when the consequences are uncapped red ink.
VRCA Stock Earnings: Verrica Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 VRCA stock results show that Verrica Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
7 Potential Short-Squeeze Stocks Poised for Rapid Gains Giving the bears a rough time can yield massive gains for contrarians, thus drawing attention to these potential short-squeeze stocks.
